Autonomix Medical, Inc. Announces Abstract Accepted for Podium Presentation at the 2025 CIRSE Annual Congress

Core Insights - Autonomix Medical, Inc. is presenting findings from its first-in-human proof-of-concept clinical trial at the 2025 CIRSE Annual Congress in Barcelona, Spain, from September 13-17, 2025 [1] - The presentation will focus on the application of artificial intelligence in interventional radiology, specifically addressing pain mitigation in pancreatic adenocarcinoma through neurolysis via transvascular radiofrequency ablation [2] Company Overview - Autonomix is a medical device company dedicated to advancing technologies for diagnosing and treating diseases of the nervous system, utilizing a catheter-based microchip sensing array for enhanced neural signal detection [4] - The company's initial focus is on treating pain associated with pancreatic cancer, a condition currently lacking reliable treatment options, with potential applications across various medical fields including cardiology and chronic pain management [5] Event Details - The presentation will be led by Marco Bedoya, VP of Research and Development, during the session titled "AI in IR: Machine Learning, SOP and Collaborative Development" on September 15, 2025, from 4:15 PM to 5:15 PM CEST [2]